| Drug Name: | Disulfiram (97-77-8) |
|---|---|
| PubChem ID: | 3117 |
| SMILES: | CCN(CC)C(=S)SSC(=S)N(CC)CC |
| InchiKey: | AUZONCFQVSMFAP-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 296.552 |
| LogP | : | 3.6212 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 6.48 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Metronidazole (443-48-1) | Acute Delusional Psychoses | Additive | The reason for this interaction is not understood, but it appears to be established. Concurrent use should be avoided or very well monitored | Toxicity of disulfiram combined with metronidazole |
| Metronidazole (443-48-1) | Confusion | Additive | The reason for this interaction is not understood, but it appears to be established. Concurrent use should be avoided or very well monitored | Toxicity of disulfiram combined with metronidazole |
| Isoniazid (54-85-3) | Drowsiness | Synergistic | Not understood. One idea is that some kind of synergy occurs between the two drugs because both can produce similar adverse effects if given in high doses. Isoniazid and disulfiram together inhibit two of three biochemical pathways concerned with the metabolism of dopamine. This leaves a third pathway open, catalysed by COMT (catechol-O-methyl transferase), which produces a number of methylated products of dopamine. These methylated products may possibly have been responsible for the mental and physical reactions seen | Possible interaction between disulfiram and isoniazid |
| Phenytoin (57-41-0) | Rise In Phenytoin Serum Levels | Synergistic | Disulfiram inhibits the liver enzymes concerned with the metabolism of phenytoin (possibly the cytochrome P450 isoenzyme CYP2C9) | Mathematical analysis of a phenytoin-disulfiram interaction |
| Clarithromycin (81103-11-9) | Epidermal Necrolysis | Additive | Not fully understood | Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy |
| Clarithromycin (81103-11-9) | Hepatitis Fulminant | Additive | Not fully understood | Fulminant Hepatitis and Fatal Toxic Epidermal Necrolysis (Lyell Disease) Coincident With Clarithromycin Administration in an Alcoholic Patient Receiving Disulfiram Therapy |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Cerebral Toxic Effect | dopamine Beta-hydroxylase (P09172) | The action of disulfiram as an inhibitor of dopamine beta hydroxylase provides a possible mechanism for the cerebral toxic effect [ ADR Type 3 ] | Catatonia due to disulfiram toxicity |
| Dyspnea | Aldehyde dehydrogenase (P47895) | Disulfiram inhibits the activities of alcohol dehydrogenase and aldehyde dehydrogenase@ respectively@leads to acute toxicity of dyspnea. [ ADR Type 1 ] | Toxicity of benzyl alcohol in adult and neonatal mice |
| Loss Of Motor Function | Aldehyde dehydrogenase (P47895) | Disulfiram inhibits the activities of alcohol dehydrogenase and aldehyde dehydrogenase@ respectively@leads to acute toxicity of loss of motor function [ ADR Type 1 ] | Toxicity of benzyl alcohol in adult and neonatal mice |
| Sedation | Aldehyde dehydrogenase (P47895) | Disulfiram inhibits the activities of alcohol dehydrogenase and aldehyde dehydrogenase@ respectively@leads to acute toxicity of benzyl alcohol of sedation. [ ADR Type 1 ] | Toxicity of benzyl alcohol in adult and neonatal mice |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category